Yenealem Temesgen-Oyelakin, BSN, RN
https://www.niams.nih.gov/about/directory/yenealem-temesgen-oyelakin-bsn-rn
Yenealem is interested in Clinical Trial research to find new and better ways to treat Lupus patients.
Displaying 221 - 240 of 1016 results
Elizabeth Elliott
https://www.niams.nih.gov/about/directory/elizabeth-elliott
Elizabeth Elliott, Ethics Coordinator, Office of the Director
Xuesong Feng, Ph.D.
https://www.niams.nih.gov/about/directory/xuesong-feng-phd
Xuesong Feng is a Staff Scientist in the Laboratory of Muscle Stem Cells and Gene Regulation.
Hong-Wei Sun, Ph.D.
https://www.niams.nih.gov/about/directory/hong-wei-sun
As head of the Biodata Mining and Discovery Section, Dr. Sun focuses on applying computational approaches of data sciences to biomedical research.
Judith Spector
https://www.niams.nih.gov/about/directory/judith-spector
Judith Spector is an Extramural Support Specialist in the Scientific Review Branch at NIAMS.
Pravitt Gourh, M.D.
https://www.niams.nih.gov/about/directory/pravitt-gourh-md
Dr. Gourh is a board-certified rheumatologist with a long-standing interest in scleroderma, and currently directs a translational research program focused on understanding the genetics of scleroderma, biomarker discovery, and disease classification.
Susana A. Serrate-Sztein, M.D.
https://www.niams.nih.gov/about/directory/susana-serrate-sztein-md
Susana A. Serrate-Sztein, M.D., Senior Advisor to the Director
Sarfaraz Hasni, M.D.
https://www.niams.nih.gov/about/directory/sarfaraz-hasni-md
Dr. Sarfaraz Hasni is a clinician, a faculty of the Rheumatology Fellowship Training Program and chief of Lupus clinical trials.
Kathy Salaita, Sc.D.
https://www.niams.nih.gov/about/directory/kathy-salaita-scd
Kathy Salaita, Sc.D., is Chief of the Scientific Review Branch, and she is responsible for the supervisory management and oversight of the Scientific Review Branch and strategic planning activities as relevant to the peer review process.
Director’s Message
https://www.niams.nih.gov/about/strategic-plan-fiscal-years-2025-2029/directors-message
The NIAMS Strategic Plan for FY 2025–2029 focuses on advancing therapy, fostering discoveries, supporting research infrastructure, and communicating health advances from the Director.
Strategic Plan Framework
https://www.niams.nih.gov/about/strategic-plan-fiscal-years-2025-2029/strategic-plan-framework
NIAMS Strategic Plan FY 2025–2029 advances research in arthritis, musculoskeletal, and skin diseases, focusing on innovation, equity, collaboration, and workforce diversity.
Introduction
https://www.niams.nih.gov/about/strategic-plan-fiscal-years-2025-2029/introduction
NIAMS, established in 1986, supports research on arthritis, musculoskeletal, and skin diseases, aiming for transformative research and equitable health outcomes.
Bold Aspirations
https://www.niams.nih.gov/about/strategic-plan-fiscal-years-2025-2029/introduction/bold-aspirations
NIAMS aims for advances in disease understanding, personalized treatments, data science, digital health, and addressing health disparities over the next five years.
Organizational Structure
NIAMS, part of NIH, supports research on arthritis, musculoskeletal, and skin diseases through extramural and intramural programs, advancing health via innovative treatments.